Growth Hormone Test Results in a Child: An Interpretation

A growth hormone (GH) stimulation test result in a child is not a simple pass-or-fail number, and reading it correctly requires understanding what the number actually reflects and, just as important, what it does not. The test measures how much GH the pituitary gland releases when provoked by a specific drug, and a peak level at or below a set cutoff (typically 10 ng/mL, sometimes lower) raises the possibility of GH deficiency. But the result sits inside a web of factors that can shift it dramatically, from the child’s weight and pubertal stage to which laboratory ran the assay. An endocrinologist will never diagnose or rule out GH deficiency on a single number alone.

Why a Random Blood Draw Cannot Measure Growth Hormone

Growth hormone does not circulate at a steady level. The pituitary releases it in pulses, mostly during deep sleep, so a random blood sample drawn during the day might catch a pulse or might catch nothing at all. A perfectly healthy child can have an undetectable GH level on a routine blood draw. That is why doctors do not use a single baseline GH measurement to assess whether a child’s pituitary is working. Instead, they use stimulation tests that force the pituitary to respond, providing a controlled window in which to judge its capacity. Various factors including age, sex, puberty, nutritional status, and body weight all modulate how much GH the pituitary secretes, which means even the stimulated response has to be read in context.¹

How Stimulation Tests Work

During a GH stimulation test, a child receives a drug designed to trigger the pituitary into releasing growth hormone. Blood samples are then drawn at timed intervals to track how high GH rises. Two of the most commonly used agents are clonidine and glucagon. In a typical protocol, clonidine is given by mouth and blood is drawn at baseline and then every 30 minutes for two hours. If the peak GH on that first test falls below a threshold, a second test using a different agent (often glucagon, given by injection) is performed at least 48 hours later, with blood drawn over a three-hour window.² The reason two tests are often required is that no single agent is perfectly reliable. A child might respond poorly to one drug but normally to another, so using two different provocative agents reduces the chance of a misleading result.

Other stimulation agents exist, including insulin (which triggers GH release through low blood sugar), arginine, and L-DOPA. The choice depends on the center’s protocol, the child’s age, and safety considerations. Insulin-induced hypoglycemia, for example, carries real risks and is generally reserved for older children under close supervision. Each agent has its own timing profile for when GH peaks, which is why the sampling schedule differs from one test to another.

What the Cutoff Numbers Mean

The traditional cutoff for GH deficiency on a stimulation test is a peak level of 10 ng/mL or below. Some centers use stricter thresholds. In one large clinical protocol, a peak below 5 ng/mL on the first test was considered strong evidence of deficiency on its own, while a peak between 5 and 10 ng/mL prompted a confirmatory second test, with the diagnosis supported only if that second test also came in at 10 ng/mL or below.² This two-tier approach reflects the reality that the 10 ng/mL cutoff is somewhat arbitrary. It was not derived from large, rigorous studies comparing deficient and healthy children; it was adopted decades ago and has stuck largely by convention.

A peak GH of 3 ng/mL tells a very different story than a peak of 9 ng/mL, even though both technically fall under the same “deficient” label. A very low peak, especially when combined with poor growth, delayed bone age, and low IGF-1 levels, points strongly toward true deficiency. A borderline result near 10 ng/mL is far more ambiguous and needs to be weighed against the full clinical picture.

The False-Positive Problem

One of the most sobering facts about GH stimulation testing is its accuracy, or lack of it. Because true GH deficiency is rare in the general population of short children, and because the stimulation tests have a meaningful false-positive rate (they sometimes report low peaks in children whose GH axis is actually fine), many positive results are wrong. One analysis estimated that among short children undergoing testing, the probability of a positive result being a true positive is only about 1 in 36.³ That means most children who “fail” a stimulation test do not actually have GH deficiency. This is the reason endocrinologists rely on clinical context, growth records, imaging, and blood markers rather than the stimulation test alone.

False negatives also happen. A child with genuine GH deficiency might produce a peak above the cutoff on a given day due to natural variability, the specific agent used, or timing. This is why experienced clinicians sometimes repeat testing or pursue additional workup even when the first stimulation result looks normal, if the rest of the clinical picture is convincing.

Why Your Child’s Weight Matters More Than You’d Think

Body weight and body composition have a direct, well-documented effect on stimulation test results. Children who are overweight or obese tend to produce lower peak GH levels on stimulation tests, even when their GH axis is perfectly healthy. A meta-analysis covering more than 2,400 children found that for every one-point increase in BMI standard deviation score, peak stimulated GH dropped by about 12%.⁴ This relationship was present even within the normal BMI range, meaning it is not only a concern for children who are clearly obese. A separate study confirmed this negative correlation, reporting that peak GH decreased by about 1 ng/mL for every one-point rise in BMI among children with isolated GH deficiency.⁵

The practical consequence is that a heavier child is more likely to be labeled GH-deficient based on the test result alone, even though the low peak may be a metabolic artifact rather than a pituitary problem. A good endocrinologist accounts for this. If your child carries extra weight, a borderline test result should prompt extra caution before concluding that GH deficiency is the explanation for short stature.

Sex Steroid Priming Before the Test

In prepubertal children who are close to the expected age of puberty, some centers administer a short course of sex steroids (estrogen for girls, testosterone for boys) before the stimulation test. The idea is that children on the cusp of puberty naturally have low sex hormone levels that dampen the GH response, potentially making a normal child look deficient. Priming with sex steroids before the test appears to correct this. In one study, children who received priming had higher peak GH values than those who did not, and the rate of conflicting results between two tests dropped from 23% in non-primed children to just 4% in primed children.⁶

Whether priming is done varies widely between institutions. Some consider it standard for any prepubertal child over a certain age; others never use it. If your child’s stimulation test was done without priming and the result was borderline, it is reasonable to ask the endocrinologist whether priming might change the picture.

The Lab Itself Can Change the Number

Here is something most parents are never told: the GH concentration reported on a lab slip depends heavily on which assay the laboratory used. Different immunoassays measuring the same blood sample can produce results that vary by more than 200%.⁷ The reasons are technical. Growth hormone in the blood exists in multiple molecular forms, and different assays detect different combinations of those forms. They also use different calibration standards, and components of the blood itself (like GH-binding protein) can interfere.⁸ A peak of 8 ng/mL at one lab might read as 12 ng/mL at another, pushing the same child across the diagnostic threshold in different directions. Efforts to standardize GH assays globally have been ongoing for years, but the problem has not been fully resolved. This is one more reason a test number in isolation is unreliable.

Supporting Blood Markers

Doctors often measure IGF-1 (insulin-like growth factor 1) and sometimes IGFBP-3 (a binding protein that carries IGF-1 in the blood) alongside or before stimulation testing. Unlike GH itself, IGF-1 is relatively stable throughout the day, making it easier to measure. However, it is not a perfect substitute for stimulation testing. A systematic review found that IGF-1 correctly identified GH deficiency about two-thirds of the time and correctly ruled it out about two-thirds of the time as well. IGFBP-3 performed similarly. Both are useful as supporting evidence, but neither is reliable enough to confirm or exclude deficiency on its own.⁹ In practice, a very low IGF-1 in a slowly growing child strengthens the case for GH deficiency, while a normal IGF-1 in the same setting makes it less likely but does not rule it out.

When a child begins GH treatment, IGF-1 levels are used to monitor dosing. The goal is to keep IGF-1 within a target range that indicates the treatment is working without overshooting into potentially risky territory. Newer long-acting GH formulations given weekly produce fluctuating IGF-1 levels over the dosing interval, with a peak a couple of days after the injection and a trough right before the next dose. Clinicians account for when in the dosing cycle the blood was drawn when interpreting these numbers.¹⁰

What Bone Age and Brain MRI Add to the Picture

A bone age X-ray of the hand and wrist is almost always part of the workup for a short child. In GH deficiency, bone maturation tends to lag behind the child’s chronological age, particularly in the smaller wrist bones. One study found that wrist bone age was significantly delayed in children with GH deficiency, though the bones of the forearm and hand did not show the same degree of delay, likely because growth hormone drives development of smaller cartilaginous bones more than larger ones.¹¹ A significantly delayed bone age in a short child with low GH levels adds weight to the diagnosis.

Brain MRI is recommended for any child diagnosed with GH deficiency, regardless of how low the test result was. The purpose is to look for structural problems in and around the pituitary gland, including small or absent glands, interrupted pituitary stalks, or tumors. A meta-analysis found that about 58% of children with non-acquired GH deficiency had pituitary or surrounding abnormalities on MRI, and the rate was dramatically higher in children with deficiencies of multiple pituitary hormones compared to those with isolated GH deficiency.¹² Children with the lowest peak GH levels on stimulation tests were more likely to have severe MRI findings, but even those with mild deficiency had abnormalities about 19% of the time.¹³ In one study, four children undergoing MRI for apparent GH deficiency were found to have craniopharyngiomas, a type of brain tumor that can compress the pituitary.¹⁴ MRI findings not only confirm the diagnosis but can change the treatment plan entirely.

When the Environment, Not the Pituitary, Is the Problem

One of the more striking phenomena in pediatric endocrinology is psychosocial dwarfism, now often called reversible somatotropin deficiency. Children living in severely neglectful or abusive environments can develop measurably low GH secretion. Their stimulation test results look like textbook GH deficiency, and their growth stalls. But when the child is removed from the harmful environment, GH secretion normalizes on its own and growth resumes without any medication.¹⁵¹⁶ The reversibility of GH insufficiency with a change in environment distinguishes this condition from organic pituitary problems. It is a vivid reminder that a low stimulation test result does not automatically mean the child’s biology is broken. The test captures a snapshot of pituitary function under specific conditions, and those conditions include emotional and environmental ones.

Rare Genetic Conditions That Mimic or Complicate Deficiency

Occasionally, a child’s test results point toward something more complex than garden-variety GH deficiency. In GH insensitivity (historically called Laron syndrome), the pituitary produces growth hormone normally or even in excess, but the body’s cells cannot respond to it because of mutations in the GH receptor gene. These children are profoundly short and have very high GH levels but very low IGF-1.¹⁷ Stimulation testing in these children shows the opposite of the expected pattern: high GH, low IGF-1. The condition is rare but important because treating it with GH injections would be pointless; the body cannot use the hormone. Instead, treatment (when available) involves IGF-1 directly. This is a situation where the test result, read without context, could lead to exactly the wrong treatment plan.

Differentiating true GH deficiency from idiopathic short stature, where children are short for no identifiable hormonal or genetic reason, remains one of the trickiest problems in the field. Some researchers are exploring whether pituitary MRI features combined with clinical data can help separate the two groups more reliably than stimulation testing alone.¹⁸ For now, the distinction often comes down to clinical judgment and response to a trial of GH therapy.

Retesting at Puberty and the Transition to Adulthood

A diagnosis of GH deficiency in childhood does not necessarily last forever. Children diagnosed with isolated idiopathic GH deficiency, meaning no structural cause was found on MRI and no other pituitary hormones were affected, have a high chance of testing normal when retested after puberty.¹⁹ In many of these cases, the childhood “deficiency” may have been a false-positive result or a transient state that resolved with the hormonal surge of puberty. By contrast, children with multiple pituitary hormone deficiencies or clear organic causes (tumors, pituitary stalk interruption) are far more likely to remain GH-deficient into adulthood.²⁰

Guidelines call for retesting during the transition from pediatric to adult endocrine care, typically in late adolescence after growth is complete. This retesting matters because GH continues to play a role in adult metabolism, bone density, and body composition. If deficiency persists, adult-dose replacement therapy may be recommended, though the doses are much lower than in childhood. Clinicians familiar with both pediatric and adult endocrinology emphasize the need for structured handoffs so that teenagers do not simply fall off the follow-up radar.²¹

Insurance and Access Realities

Even when test results clearly support a GH deficiency diagnosis, getting treatment covered is its own obstacle course. GH therapy is expensive, and insurance coverage varies widely depending on the diagnosis and the insurer. Coverage for classical GH deficiency is generally the least controversial, but for conditions like Turner syndrome, chronic kidney disease, or idiopathic short stature, approval rates differ enormously. One study of U.S. insurance policies found that Medicaid programs approved GH for Turner syndrome about 81% of the time, while some private insurers approved it only 25% of the time. For idiopathic short stature, none of the surveyed private or Blue Cross/Blue Shield insurers approved coverage, while about half of Medicaid agencies did.²² Some insurers also restrict prescribing authority to pediatric endocrinologists, meaning families in underserved areas without specialist access face additional barriers. These coverage differences mean that two children with identical test results and clinical histories may end up with very different treatment paths depending on who provides their insurance.